Unique toxicities issues were not seen with ramucirumab and pembrolizumab. The adverse events aligned with known side effects of the individual agents as previously reported. Toxicities were less than those seen in the standard of care arm. Many patients are interested to learn about a potentia...

In S1800A, grade ≥3 treatment-related adverse events occurred in 42% of patients in the ramucirumab/pembrolizumab group and 60% in the SOC group. Also, fewer patients on ramucirumab/pembrolizumab vs. on SOC discontinued treatment due to adverse events. Overall, the safety profile seen with ramuci...